

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number  
**WO 02/44427 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number: PCT/US01/51234

(22) International Filing Date: 25 October 2001 (25.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/243,689 27 October 2000 (27.10.2000) US

(71) Applicant (for all designated States except US): **PRESIDENT AND FELLOWS OF HARVARD COLLEGE**  
[US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KIM, Tae Kook**  
[KR/US]; 11 Beecher Terrace, #2, Newton, MA 02459 (US).

(74) Agent: **BAKER, C., Hunter**; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DOUBLE AND TRIPLE READOUT ASSAY SYSTEMS



(57) Abstract: The present invention provides assays for identifying compounds that affect the transcriptional activity of a protein of interest or affect the stability of the protein of interest. The triple readout assay system which can be used to identify compounds that affect the transcriptional activity of a protein of interest uses three cell lines to control for non-specific effects such as sequences flanking the inserted gene and cytotoxicity. The double readout assay system assesses protein stability and uses a fusion protein of a reporter and the protein of interest. These assay systems may be particularly useful in identifying compounds that affect transcription factors and tumor suppressors. In a particular embodiment, the tumor suppressor p53 is the target protein being studied.

WO 02/44427 A2

## DOUBLE AND TRIPLE READOUT ASSAY SYSTEMS

### Related Applications

- 5           The present application claims priority to co-pending provisional application, USSN 60/243,689, filed October 27, 2000, which is incorporated herein by reference.

### Background of the Invention

- 10           Pharmaceutical screens and biological assays have been used for decades in the pharmaceutical and biotech industries to identify lead compounds in the search for new pharmaceutical agents. In the last decade, the chemist's ability to synthesize large numbers of chemical compounds in a short amount of time through techniques such as combinatorial chemistry has greatly increased (for a recent review of the area  
15 of combinatorial chemistry, please see Geysen *et al. Molec. Immunol.* 23:709-715, 1986; Houghton *et al. Nature* 354:84-86, 1991; Frank *Tetrahedron* 48:9217-9232, 1992; Bunin *et al. Proc. Natl. Acad. Sci. USA* 91:4708-4712, 1994; Thompson *et al. Chem. Rev.* 96:555-600, 1996; Keating *et al. Chem. Rev.* 97:449-472, 1997; Gennari *et al. Liebig's Ann./Recueil* 637-647, 1997; Reddington *et al. Science* 280:1735-1737,  
20 1998; each of which is incorporated herein by reference), and it has expanded beyond the capacity of traditional screening methods. Often, thousands to millions of compounds need to be screened to identify those having a desired pharmaceutical property (*e.g.*, anti-neoplastic activity, immunosuppressive activity, *etc.*). Many of the currently available screens are biochemical assay systems in which a compound is  
25 added to a purified or partially purified cell extract to see if it possesses the desired activity. In contrast to the biochemical assay systems, currently available cell-based assay systems identify bioactive molecules that are cell-permeable and work within physiological environments. However, one of the major drawbacks to cell-based assay screens is the high false-positive rate resulting from non-specific effects of the  
30 compound within the cell (for examples, please see Sarver *et al. AIDS Res. Hum. Retroviruses* 8:659-666, 1992; Witvrouw *et al. Antimicrob. Agents Chemother.* 36:2628-2633, 1992; each of which is incorporated herein by reference). Given the fundamental importance of gene regulation in many disease states, one typical cell-based assay measures the activity of a reporter gene under the control of a specific  
35 reporter. However, inhibition of reporter gene expression does not necessarily

indicate a specific interference with promoter activity but could reflect a non-specific inhibition of cellular functions, for example due to cytotoxicity.

One particularly important protein in the study of cancer is the nuclear phosphoprotein, p53. p53 is thought to be mutated in over 50% of human cancers.

5 Mutations in the p53 gene have been found in tumors of colon, lung, breast, ovary, bladder, and several other organs. When mutant forms of the p53 gene are introduced into primary fibroblasts, these cells become immortalized. The wild type p53 gene has been shown to suppress the growth of transformed human cells, but oncogenic forms of p53 lose this suppressor function. Therefore, the p53 gene has been termed a  
10 “tumor suppressor” gene. Given the role of p53 in tumorigenesis, it has become an important potential target in the search for new anti-neoplastic agents.

The wild type p53 may be interfered with functionally. For example, a transforming viral infection of the cell can interfere with the p53 protein product. For instance, certain strains of human papillomavirus (HPV) are transforming and are  
15 known to interfere with the level of p53 protein in the infected cell because the virus produces a protein, E6, which promotes degradation of the p53 protein.

There is also an interest in p53 because p53 protein is capable of inducing apoptosis in certain cells. In apoptosis, or “programmed cell death”, a series of lethal events for the cell appear to be generated directly as a result of transcription of  
20 cellular DNA. For example, lymphocytes exposed to glucocorticoids die by apoptosis. Involution of hormone sensitive tissue such as breast and prostate that occurs when the trophic hormone is removed occurs via apoptosis.

In particular, recent studies have indicated that the introduction of wild type (non-mutated) p53 into transformed cell lines that carry a mutant form of p53 induces  
25 the cells to undergo apoptosis with disintegration of nuclear DNA. It is believed that p53 may suppress tumor development by inducing apoptosis, thus modulating cell growth.

Given the importance of p53 in a variety of physiological and disease states, there is a need for cell-based assays with low backgrounds that could be used in  
30 screening compounds to identify inhibitors and activators of p53. Moreover, both the rapid increase of new drug targets through genomics research and the availability of vast libraries of chemical compounds create an enormous demand for new technologies which would improve the screening process.

### Summary of the Invention

The present invention provides assay systems for screening chemical compounds to identify activators and inhibitors of proteins of interest (*e.g.*,  
5 transcription factors, enzymes, and tumor suppressors).

In one aspect, the invention provides a cell-based triple readout assay system for identifying compounds that affect transcriptional activity. Three separate cell lines, each containing a different engineered construct, are used. Two have been transfected with a construct comprising a reporter gene and a modulatable  
10 transcriptional regulatory sequence known to bind a selected transcription factor. Each of the two cell lines has a different reporter gene, and the construct is integrated into the genome in a different location to control for the effect of flanking sequences on the transcription of the reporter gene. A third cell line has been transfected with a construct comprising a third reporter gene operably linked to a constitutive promoter.  
15 The third cell line is used to assess general cytotoxicity of the test compound. At least one cell derived from each of the three cell lines is contacted with the test compound, and the levels of the reporter genes are assayed and used to determine the specificity of the test compound on the transcription factor or transcription factor pathway. In a particularly preferred embodiment, the transcription factor of interest is p53.

20 In another aspect, the invention provides a cell-based double readout assay system for identifying compounds that affect protein stability/levels in cells. A fusion protein is created between a protein of interest and a first reporter protein. The fusion protein and a second reporter protein are expressed in a cell line to which the test compound is added. The second reporter protein is used to control for non-specific  
25 effects such as cytotoxicity. The levels of the two proteins (*i.e.*, the fusion protein and the second reporter protein) are measured to assess the specificity of the test compound on the protein of interest. In a particularly preferred embodiment, the two proteins are translated from the same mRNA transcript of an engineered DNA construct.

30 In a particularly preferred embodiment of this aspect of the present invention, the protein of interest is p53. One critical point of regulation of p53 occurs at the protein level. Tumor mutations that affect its conformation typically increase its half-life, in part by inhibiting its degradation by the ubiquitin-proteasome pathway.

Consistent with its critical role in tumor suppression, many oncoproteins including human papillomavirus E6 oncoprotein target the p53 protein and alter its stability.

In yet another aspect, the invention provides chemical inhibitors and activators of p53. Such inhibitors and activators may preferably be identified and/or  
5 characterized using one or both of the inventive triple and double readout assay systems. In certain clinical situations, it is desirable to suppress the cellular effects of p53. For example, p53-dependent apoptosis is thought to contribute to the toxic side effects of anti-cancer treatment with chemotherapy. In certain preferred embodiments of the invention, the p53 inhibitors or activators are provided in the context of a  
10 pharmaceutical composition. In a preferred embodiment, the inhibitors and activators are small molecules.

In another aspect, the invention provides kits for performing the double and triple readout assays. Preferably, an inventive kit contains all the reagents needed to assay a test compound for its effect on transcription and/or protein stability/levels. In  
15 a particularly preferred embodiment, a kit to be used in performing the triple readout assay contains the three cell lines described above. A kit for performing the double readout assay preferably contains a cell line stably transfected with a fusion protein and a second reporter protein. In another preferred embodiment, an inventive kit comprises DNA constructs to be used in transfecting a cell line. Preferred inventive  
20 kits may also contain additional reagents such as media for growing the cells, enzyme substrates (*e.g.*, the substrate of luciferase), DNA damaging compounds (*e.g.*, adriamycin), human papillomavirus E6 oncoprotein, growth factors, *etc.*

### Definitions

25 Unless indicated otherwise, the terms defined below have the following meanings:

“Compound”: The term “compound” or “chemical compound” as used herein can include organometallic compounds, polynucleotides, oligonucleotides, peptides, proteins, organic compounds, metals, transitional metal complexes, and small  
30 molecules. In a particularly preferred embodiment, the term compound refers to small molecules (*e.g.*, preferably, non-peptidic and non-oligomeric) and excludes peptides, polynucleotides, transition metal complexes, metals, and organometallic compounds.

“Constitutive promoter”: The term constitutive promoter refers to a promoter that is always “on”. In other words, genes operably linked to a constitutive promoter are always being transcribed to produce mRNA.

“Construct”: The term construct refers to any polynucleotide that has been manipulated by the hand of man. Specifically, the construct is isolated from other sequences that are found in the natural state. The construct may be produced by recombinant known in the art such as the polymerase chain reaction. Preferably, the polynucleotide contains various elements that are operably linked, and the construct is introduced into a cell. For example, the construct may contain a promoter operably linked to a coding sequence, and the construct may be introduced into a cell to cause the cell to produce the encoded protein. In a preferred embodiment, the construct has been created or engineered by the hand of man and does not occur naturally.

“Fusion protein”: The term “fusion protein” refers to a protein comprising two or more polypeptides that, although typically unjoined in their native state, are joined by their respective amino and carboxyl termini through a peptide linkage to form a single continuous polypeptide. The two or more polypeptide components can be either directly joined or indirectly joined through a peptide linker/spacer. The fusion protein may be translated by a ribosome from mRNA as a single polypeptide, or the polypeptides may be joined using synthetic or enzymatic chemistry.

“Modulatable transcriptional regulatory sequence”: The term “modulatable transcriptional regulatory sequence” refers to a DNA sequence capable of regulating the initiation of transcription from the promoter of the reporter gene by the binding of a protein to the sequence. The protein preferably binds a regulatory sequence of the construct in which the promoter, modulatable transcriptional regulatory sequence, and reporter gene are operably linked, and thereby the protein either up-regulates or down-regulates the transcription from the promoter.

“Operably linked”: The term operably linked refers to two segments of polynucleotide sequence that can affect each other. In a particularly preferred embodiment, one of the two segments is a sequence that binds a protein (*e.g.*, polymerase, enhancer, and transcription factor), and the binding of the protein to the sequence leads to the transcription of a gene sequence located in the second segment. In another particularly preferred embodiment, the binding of a molecule (*e.g.*, nucleic acid, small molecule, protein, and peptide) to one segment may inhibit or enhance the binding of another molecule (*e.g.*, nucleic acid, small molecule, protein, and peptide)

to the second segment. Preferably, two operably linked segments are covalently linked, but any type of association sufficient to achieve the desired results is considered to be operably linked in the context of the present invention.

“p53”: The term “p53” as used in the present invention refers to both the gene and protein form of p53 or any homolog of p53 or member of the family of p53 genes. The homolog should be at least 50% homologous to the mouse p53 DNA or protein sequence; preferably, at least 60% homologous, and most preferably, greater than 75% homologous. A homolog of p53 may also be identified by its activity such as its ability to suppress the growth of transformed cells. In another preferred embodiment, the homolog of p53 is identified by its location in the genome (*e.g.*, location on the chromosome). In yet another preferred embodiment, the homolog of p53 is able to hybridize to the p53 gene under standard hybridization conditions. p53 may also refer to a fragment of a p53 gene. In certain preferred embodiments, p63, p73, and homologs thereof are considered to be p53 family members. In other preferred embodiments, homologs are at least 50% homologous within the central sequence-specific DNA binding domain, the N-terminal transactivation domains, and/or the C-terminal oligomerization domain, more preferably greater than 60% homologous.

“p53 binding element”: The term “p53 binding element” refers to a sequence of a polynucleotide that binds the p53 protein. In a preferred embodiment, the p53 binding element is the p53 binding element found in the p21, bax, or 14-3-3 gene. The p53 binding element may comprise multiple binding elements (*i.e.*, be multimerized).

“Polynucleotide” or “oligonucleotide”: Polynucleotide or oligonucleotide refers to a polymer of nucleotides. Preferably, the polynucleotide comprises at least three nucleotides, more preferably it comprises at least 10 nucleotides, and most preferably it comprises at least 100 nucleotides. The polymer may include natural nucleosides (*i.e.*, adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (*e.g.*, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (*e.g.*, methylated bases), intercalated bases, modified

sugars (*e.g.*, 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), or modified phosphate groups (*e.g.*, phosphorothioates and 5'-N-phosphoramidite linkages).

“Protein”: According to the present invention, a “protein” comprises a polymer of amino acid residues linked together by peptide bonds. The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. Typically, a protein will be at least three amino acids long. Peptide may refer to an individual peptide or a collection of peptides. Inventive peptides preferably contain only natural amino acids, although non-natural amino acids (*i.e.*, compounds that do not occur in nature but that can be incorporated into a polypeptide chain; see, for example, <http://www.cco.caltech.edu/~dadgrp/Unnatstruct.gif>, which displays structures of non-natural amino acids that have been successfully incorporated into functional ion channels) and/or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in an inventive peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a hydroxyl group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, *etc.* A protein may also be a single molecule or may be a multi-molecular complex. A protein may be a fragment of a naturally occurring protein or peptide. A protein may be naturally occurring, recombinant, or synthetic, or any combination of these.

“Reporter gene”: As used herein, the term “reporter gene” refers to a gene whose transcript or any other gene product (*e.g.*, protein) is detectable. Preferably, the gene product is also quantifiable. More preferably, the gene product is detectable using a standard assay. Most preferably, the gene product is detectable using a standard assay for which the reagents used in the assay are available in a kit. In certain preferred embodiments, the reporter gene encodes a fluorescent protein or an enzyme whose activity is detectable and preferably quantifiable.

“Small Molecule”: As used herein, the term “small molecule” refers to a non-peptidic, non-oligomeric organic compound either synthesized in the laboratory or found in nature. Small molecules, as used herein, can refer to compounds that are “natural product-like”, however, the term “small molecule” is not limited to “natural product-like” compounds. Rather, a small molecule is typically characterized in that it contains several carbon-carbon bonds, and has a molecular weight of less than



1500, although this characterization is not intended to be limiting for the purposes of the present invention. Examples of "small molecules" that occur in nature include, but are not limited to, taxol, dynemicin, and rapamycin. Examples of "small molecules" that are synthesized in the laboratory include, but are not limited to, compounds described in Tan *et al.*, ("Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays" *J. Am. Chem. Soc.* 120:8565, 1998) and pending application number 08/951,930 "Synthesis of Combinatorial Libraries of Compounds Reminiscent of Natural Products", the entire contents of which are incorporated herein by reference.

### Description of the Drawing

Figure 1 shows the transcriptional activation of p53 binding sites. (A) Six copies of p53 binding sites from p21, bax, and 14-3-3 gene, and (B) multiple copies (3, 6, and 12) of the p53 site from 14-3-3 gene were cloned upstream of FL (firefly luciferase) reporter gene. RKO cells were transfected with these plasmids and reporter activities were analyzed after treatment with adriamycin. The results are presented as fold induction, compared to the luciferase activities from cells untreated with adriamycin.

Figure 2 shows a reporter plasmid used for p53 transcriptional activity. Twelve copies of the p53 site from 14-3-3 gene were cloned upstream of FL (firefly luciferase) or SEAP (secreted alkaline phosphatase) reporter gene. This reporter plasmid was used to monitor the transcriptional activity of p53 in cells.

Figure 3 shows transcriptional activation of p53 in a selected stable cell line by DNA damaging agents. (A) FL (firefly luciferase) and (B) SEAP (secreted alkaline phosphatase) reporter activities were determined in the selected clone of stably transfected RKO cells before and after treatment with various DNA damaging agents (adriamycin, UV radiation, mitomycin C, and etoposide). The results are presented as fold induction, compared to the reporter activities from untreated cells.

Figure 4 shows triple readout for p53 transcriptional activity. An equal number of each of the three different RKO reporter cell lines (containing FL and SEAP under the control of p53, an RL under the control of the CMV promoter) was cultured in each well of 384-well plates. Chemicals were transferred into the wells

using pin arrays and preincubated with cells before addition of adriamycin (0.5-1.0  $\mu$ M). After ~24 hours, SEAP activity was determined from culture media using the SEAP Assay System (Promega). FL and RL activities were determined from cell lysates using the Dual Luciferase Assay System (Promega). In the screens, we  
5 identified chemicals that specifically affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

Figure 5 shows stabilization of p53 protein by DNA damaging agents and destabilization of p53 protein by E6 oncoprotein. (A) p53-FL (firefly luciferase) and RL (renilla luciferase) reporter activities were determined in the selected MCF7 clone  
10 before and after treatment with adriamycin. The results are presented as fold induction (p53-FL/RL), compared to the luciferase activities from cells untreated with adriamycin. (B) p53-FL and RL reporter activities were determined in the selected MCF7 clone in the absence or presence of expression of E6 oncoprotein. The results are presented as fold induction (p53-FL/RL), compared to the luciferase activities  
15 from untreated cells.

Figure 6 shows a reporter plasmid used for p53 protein stability and levels. The p53 gene was fused with FL (firefly luciferase) reporter gene. p53-FL fusion protein was expressed together with RL (renilla luciferase) reporter protein through IRES (internal ribosome entry site) under the control of CMV promoter. This reporter  
20 plasmid was used to monitor the stability of p53 protein in cells.

Figure 7 shows the double readout assay for p53 protein stability. A 384-well plate was used to culture MCF7 cells expressing p53-FL and RL proteins, both under control of the CMV promoter. Chemicals were transferred into 384-well plates using pin arrays and preincubated with cells before addition of adriamycin (1  $\mu$ M). After  
25 ~24 hours, p53-FL and RL activities were determined from cell lysates using the Dual Luciferase Assay System (Promega). In the screens, chemical compounds were identified that specifically affect the stability/levels of p53-FL protein, without affecting those of the RL protein.

Figure 8 shows specific chemicals identified from multiple readouts. (A) The  
30 triple and double readout systems were effectively used to screen specific chemicals in a diverse collection of 16,320 synthetic chemicals (Chembridge Corporation), which affect the transcriptional activity and protein stability of p53, respectively. (B) Shown in an example of the selected chemicals which affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

Figure 9 shows double and triple readouts for signaling pathways as a drug-discovery platform. Using multiple readouts, these assays can be used to effectively screen for small molecules specific to p53. Some chemicals may affect transcriptional activity of p53 by up-regulating or down-regulating p53 protein levels.

5 The other chemicals, those whose activity was detected in the triple readout, but not the double readout, presumably modulate p53 transcriptional activity without affecting p53 protein stability. Thus, these readouts enabled us to select and categorize chemicals with potent and specific effects on p53 protein stability and/or transcriptional activity. These assay systems lay out the basis of systematic screening

10 for specific chemical ligands in many other signaling pathways.

### Description of Certain Preferred Embodiments

The present invention provides systems for identifying inhibitors and

15 activators of genes and gene products using cell-based assays with built-in controls to minimize the number of non-specific hits (*i.e.*, background). The inventive assay systems eliminate the need for multiple screenings, which can be costly and time-consuming. The inventive assays determine the effect of a test compound on transcription and levels/stability of the protein of interest.

20

#### *Triple Readout Assay System*

The present invention provides a cell-based triple readout assay system that involves the measurement of the activity or level of a reporter gene product under the control of a specific promoter. Past efforts to assay reporter gene activity were

25 complicated by problems including non-specific inhibition of reporter gene expression, which could be due to non-specific inhibition of cellular functions by cytotoxicity. Before the present invention, in order to distinguish between "true" inhibition and other non-specific effects, a number of time-consuming and costly experiments would need to be performed. Also, another problem associated with

30 many available reporter gene assays is that upon integration of the reporter gene into the genome the transcription of the reporter gene could be influenced by DNA sequences around which the reporter gene was stably inserted.

The inventive triple readout assay overcomes these limitations and therefore reduces or eliminates the need for multiple screenings. The inventive cell-based triple

readout assay involves three separate cell lines. Two of the cell lines express a reporter gene under the control of the same modulatable transcriptional regulatory sequence. The third cell line expresses a reporter gene under the control of a constitutive promoter. The influence of the DNA sequences adjacent to where the reporter gene was stably inserted is controlled for by the first two cell lines. General effects of cytotoxicity or inhibition of gene expression are eliminated using the third cell line that uses a constitutive promoter.

In a particularly preferred embodiment, the transcription factor being studied is p53. In unstressed cells, p53 is present at low levels and exists in a latent, inactive form. Levels and/or activity of p53 increase in response to a variety of stimuli including genotoxic stress. Active p53 protein accumulates in the nucleus, binding to its responsive DNA elements and inducing the transcription of its target genes. Under inappropriate growth conditions, p53 can integrate a variety of signals to the specific gene regulation for protection of cells against neoplastic transformation. Consistent with its critical role in tumor suppression, the majority of the p53 mutations associated with human tumors, in addition to many oncoproteins, decrease p53's sequence-specific DNA binding and transcriptional activity. Thus, small molecules that modulate transcriptional activity of p53 are important for therapeutic purposes.

Any cell line may be used in developing the cell lines used in the inventive triple readout assay. The cells may be animal, plant, bacterial, or fungal cells. In a preferred embodiment, the cell line is a mammalian cell line. In a particularly preferred embodiment, the cell line is a human cell line. The chosen cell line may satisfy other requirements particular to the protein of interest and known to one of skill in this art; for example, if one were interested in regulating p53-dependent transcription, the cell line should preferably (1) express wild-type p53; (2) show a high level of induction of p53 after treatment with DNA damaging agents; and/or (3) have functionally intact p53-mediated growth arrest pathways. A particularly preferred cell line used in studying p53 is the RKO cell line, a colon cancer cell line. Those of ordinary skill in this art will readily appreciate the multitude of cell lines that could be utilized in the assay systems and would be able to choose a cell line based on multiple factors affecting the gene or protein being studied in the inventive assay.

The modulatable transcriptional regulatory sequence is modulated by the protein of interest or by a protein which is secondarily or indirectly modulated by the protein of interest. In some embodiments, the protein of interest directly modulates

transcription by binding to the regulatory sequence directly or indirectly. In other embodiments, the protein of interest acts indirectly to modulate transcription. The protein of interest may act indirectly through a single- or multi-step biological pathway. The responsiveness of the regulatory sequence may depend on the presence  
5 or absence, or activity level, of the protein of interest.

To give but one example, in which p53 is the protein of interest, the modulatable transcriptional regulatory sequence comprises at least one p53 binding element. Any p53 binding element may be operably linked to the reporter gene. In a preferred embodiment, the p53 binding element shows a high level of induction of the  
10 operably linked reporter gene in response to DNA damage. Examples of p53 binding elements can be found in the following three target genes: p21, bax, and 14-3-3. In a particularly preferred embodiment, the p53 binding element is multimerized. For example, six to twelve copies of the element may result in nearly saturated levels of p53 induction. In other embodiments, the p53 may act as a repressor, and down-  
15 regulation of the reporter gene is assayed.

The reporter gene may encode any gene product (*i.e.*, transcript and protein) that is detectable by any known method (*e.g.*, Northern analysis, Western analysis, radio-immuno assay, enzymatic assay, change in fluorescence, change in absorbance, *etc.*), and preferably the level of the gene product is quantifiable by any known  
20 method (please see, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); the treatise, *Methods in Enzymology* (Academic Press, Inc., N.Y.); *Immunochemical Methods in Cell and Molecular Biology* (Mayer and Walker, eds., Academic Press, London,  
25 1987); Ausubel *et al.* *Current Protocols in Molecular Biology* (John Wiley & Sons, Inc., New York, 1999); *Transcription and Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Handbook of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); each of which is incorporated herein by reference). In a preferred embodiment, the reporter gene is an enzyme (*e.g.*, kinases, phosphatases,  
30 luciferases,  $\beta$ -galactosidase, reductases, synthases, horseradish peroxidase, synthetases, *etc.*). The enzyme itself may be detectable or the activity of the enzyme may be used to indirectly measure the level of the enzyme.

In a particularly preferred embodiment of the present invention, at least one of the reporter genes of the assay system encodes a luciferase protein. Luciferases may

come from any organism including the North American firefly, *Photinus pyralis*, the sea pansy, *Renilla reniformis*, and the bacterium, *Vibrio fischeri*. A more complete description of luciferases and their use as transcriptional reporters can be found in De Wet *et al.* ("Cloning of firefly luciferase cDNA and the expression of active luciferase in *Escherichia coli*" *Proc. Natl. Acad. Sci. USA* 82:7870, 1985; incorporated herein  
5 by reference) and Engebrecht *et al.* ("Measuring gene expression with light" *Science* 227:1345, 1985; incorporated herein by reference).

In another particularly preferred embodiment of the present invention, at least one of the reporter genes of the assay system encodes an alkaline phosphatase. The  
10 phosphatase gene may be from any species. A particularly preferred alkaline phosphatase is secreted alkaline phosphatase (SEAP).

In another particularly preferred embodiment, the reporter gene encodes an enhanced green fluorescent protein (EGFP). For more details in the use of enhanced green fluorescent protein as a reporter, please see Cinelli *et al.* (*Photochem.*  
15 *Photobiol.* 71(6):771-776, 2000; incorporated herein by reference); Kiss-Toth *et al.* (*J. Immunol. Methods* 239(1-2):125-135, 2000; incorporated herein by reference); and Millet *et al.* (*Toxicol. Sci.* 55(1):69-77, 2000; incorporated herein by reference).

#### *Double Readout Assay System*

20 The level of certain proteins in the cell regulates many cellular processes. Therefore, the degradation, stability, and accumulation of proteins are highly controlled in the cell. For example, one pathway which regulates the degradation of proteins is the ubiquitin-proteasome pathway. The ability to regulate specific protein degradation pathways or to affect the stability of specific proteins would allow for a  
25 new approach in treating diseases such as cancer, autoimmune diseases, and neurological diseases.

Traditional assays for identifying compounds that effect protein stability have been hampered by the large number of non-specific effects. For example, an increase in protein stability may reflect a non-specific inhibition of cellular functions by the  
30 cytotoxic effect of the compound rather than a specific effect on the protein's stability.

To give but one example of a protein whose level is critical in a cellular process, p53 is a tumor suppressor protein whose level has been found to be important in tumorigenesis. Mutations in p53 that affect its conformation typically increase its

half-life, in part by inhibiting its degradation by the ubiquitin-proteasome pathway. In unstressed cells, p53 is present at low levels and exists in a latent, inactive form. If the cell is then stressed (*e.g.*, genotoxic stress), the levels and/or activity of p53 increase. Active p53 protein then accumulates in the nucleus of the cell, binds to its responsive DNA elements, and induces the expression of its target genes. Under inappropriate growth conditions, p53 can integrate a variety of signals for protection of the cells against neoplastic transformation. Consistent with p53's critical role in tumor suppression, many oncoproteins target p53 and its protein stability, including the human papillomavirus E6 oncoprotein. Therefore, compounds that could modulate p53 protein stability are important for therapeutic purposes.

In the inventive double readout assay system, the protein of interest (*e.g.*, p53) is fused to a first reporter protein, for example using standard recombinant DNA techniques (Ausubel *et al.*, *Current Protocols in Molecular Biology* (John Wiley & Sons, Inc., New York, 1999); Sambrook, Fritsch, and Maniatis, eds., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., (Cold Spring Harbor Laboratory Press, 1989); each of which is incorporated herein by reference). Both the fusion protein and a control reporter protein are expressed in the cell. The cell(s) are contacted with various test compounds, and the levels of the fusion protein and the control reporter protein are measured. The level of the fusion protein when compared to the level of the control reporter protein would allow for the identification of compounds specifically affecting the stability of the protein of interest due to their effects on the ratio of fusion protein to control. In a preferred embodiment, at least a 50% change in the level of the fusion protein when compared to that of the control reporter protein is considered to be a hit, more preferably there is at least a 150% change, and most preferably there is at a 500% change.

The reporter proteins may be any protein or peptide as described above in the triple readout assay system. Preferably, the presence of the protein or peptide can be detected using standard techniques (*e.g.*, radioimmunoassay, radio-labeling, immunoassay, assay for enzymatic activity, absorbance, fluorescence, luminescence, and Western blot). More preferably, the level of each of the reporter proteins is easily quantifiable using standard techniques even at low levels. In a preferred embodiment, the reporter proteins are related so that their levels are easily comparable.

In a particularly preferred embodiment, the reporter proteins are luciferases as described above in the triple readout assay system. Preferably, the luciferases are

distinguishable from one another if two luciferases are used as the reporter proteins. In a particularly preferred embodiment, one reporter protein is firefly luciferase (FL) from *Photinus pyralis*, and the other is *Renilla* luciferase (RL) from *Renilla reniformis*. The protein levels may be determined using the Dual-Luciferase<sup>®</sup> Assay System (Promega) (*Dual-Luciferase<sup>®</sup> Reporter 1000 Assay System*, Technical Manual No. 046, Promega Corp., Madison, WI, 1999; incorporated herein by reference).

Preferably, the genes encoding the fusion protein and the control reporter protein are transcribed at substantially the same level. In a particularly preferred embodiment, the two genes of the proteins are transcribed together to create one transcript. An internal ribosome entry site (IRES) may be inserted between the two genes to ensure translation of both encoded proteins. In another particularly preferred embodiment, the two genes are under the control of the same promoter sequences and regulatory elements.

As with the inventive triple readout assay system, any cell line in which the proteins are expressed may be employed in the inventive double readout system. Preferably, in the example of p53, the cell line contains active p53 turnover pathways, the steady-state level of p53 protein is relatively low, and the level of p53 protein significantly increases following stress stimuli (*e.g.*, treatment with chemotherapeutic DNA damaging agents). In a particularly preferred embodiment, the cell line is MCF7.

In another particularly preferred embodiment, the cell line is transfected with the fusion protein gene and the control reporter gene, and the resulting cells are tested for stabilization of p53 protein after treatment with adriamycin. Preferably, the clones show a 5-fold increase in the level of the fusion protein. More preferably, the clones show a 10-fold increase; and most preferably, the clones show a 20-fold increase.

The cell line may be transfected with other genes that affect p53 degradation. In a particularly preferred embodiment, the cell line is transfected with the human papillomavirus oncoprotein E6. Many other oncoproteins may be used in this embodiment of the invention. As will be appreciated by one of skill in this art, any gene that may affect the stability/level of the protein being investigated may be transfected into the cell line.

### *Test Compounds*



The compounds to be screened in the inventive double and triple readout assays may be provided by any means known in the art. The test compounds may be polynucleotides, peptides, proteins, small molecules, organic molecules, inorganic molecules, peptidomimetics, antibodies, or other chemical compounds. The compounds may be prepared by purification or isolation from a source (*e.g.*, plant, fungus, animal, bacteria, soil sample, *etc.*), or by synthesis. The synthesized compounds may be created by more conventional one-by-one synthetic methods or by combinatorial chemistry methods through rapid parallel and/or automated synthesis. The compounds may be provided in crude or pure forms. The compounds may be natural products or derivatives of natural products. In another preferred embodiment, the compounds are provided from the historical compound files of large pharmaceutical and chemical companies. Preferably, the compounds are provided as libraries of chemical compounds.

The compounds are screened by the methods described above to identify activators and inhibitors of the protein/gene of interest. To give but one example, the methods may be used to identify activators and inhibitors of p53. Chemical inhibitors of p53 are useful in preventing or minimizing the toxic side effects derived from p53-dependent apoptosis (*e.g.*, those side effects seen in individuals undergoing chemotherapy and radiation therapy). Chemical activators of p53 would be useful in developing new anti-neoplastic agents. In a particularly preferred embodiment, the compounds may activate or inhibit the protein/gene of interest by two-fold, more preferably five-fold, and most preferably ten-fold.

#### *Kits*

The present invention also provides kits for performing the double and triple readout assays. Preferably, these kits include all the reagents necessary to assay a test compound or library of test compounds. The kits may include cell lines, stably transfected cell lines as described above, media, growth factors, DNA damaging agents (*e.g.*, bleomycin, adriamycin), human papillomavirus E6 oncoprotein, DNA constructs, enzyme substrate (*e.g.*, substrate of the luciferase enzyme being assayed for), *etc.*

These and other aspects of the present invention will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain particular embodiments of the invention but are not intended to limit its scope, as defined by the claims.

5

### Examples

#### Example 1- Triple Readout for p53 Transcriptional Activity

Three different reporter cell lines (one containing FL under the control of p53, a second containing SEAP under the control of p53, and a third containing RL under the control of the CMV promoter) were established by selection with hygromycin (400  $\mu\text{g/mL}$ ) after transfection of RKO cells with the reporter plasmid (see Figure 2). In the screen, cells derived from the three cell lines were mixed, and the activities of the three different reporter proteins were assayed in a single well after incubation with chemicals as described below.

15 The cells lines were maintained in McCoy media supplemented with antibiotics and 10% heat-inactivated fetal bovine serum (FBS) to exclude SEAP activity in the serum. After monomerization of reporter cells with trypsin, an equal number of cells from each of the three cells lines was mixed in a flask, and 30  $\mu\text{L}$  of the resulting cell mixture was dispensed in each well of a 384-well plate ( $5 \times 10^3$  cells/well) using an automatic dispenser (Multidrop 384, Labsystems). After 12-16 hours, test chemical compounds were introduced into the wells using pin arrays resulting in a final concentration of  $\sim 5 \mu\text{g/mL}$  of the test compound and pre-incubated with the cells for 2 hours followed by the addition of adriamycin (0.5-1.0  $\mu\text{M}$ ). After 24 hours, activities of reporter proteins were determined using corresponding assay systems according to the manufacturer's instructions.

25 For the SEAP assay, 5  $\mu\text{L}$  of each of the culture media was transferred to another 384-well plate and incubated with 55  $\mu\text{L}$  of the SEAP assay mixture (EscAPe SEAP Chemiluminescent Assay System, Clontech Laboratories) at room temperature for 20 minutes. SEAP activity was measured using a luminescent reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences).

30 The Dual Luciferase Reporter Assay System (Promega) was used for FL and RL assays. In the original 384-well culture plate, the remaining media was removed, and the cells were washed once with 40  $\mu\text{L}$  of phosphate buffer-saline (PBS). The washed cells were incubated with Passive Lysis Buffer (PLB, 5  $\mu\text{L}$ /well) for 20

minutes at room temperature with mild-shaking. Then, the Luciferase Assay Reagent II (LAR II, 25  $\mu$ L/well) was added directly to the cell lysates, and FL activity was determined using a luminescent reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences). After measuring the FL activity, Stop & Glo Reagent (25  $\mu$ L/well) was  
5 added, and the RL activity was determined. In the screens, chemical compounds were identified that specifically affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

#### Example 2 – Double Readout Assay for p53 Protein Stability

10 A plasmid expressing both the p53/FL fusion gene and RL gene under the control of a single CMV promoter with an internal ribosome entry site (IRES) was created (see Figure 6). Co-expression of p53/FL and RL proteins by taking advantage of the internal ribosome entry site makes it possible to normalize the levels of p53/FL with those of RL in various assay conditions. The reporter cell line was established  
15 by selecting MCF7 cells transfected with the IRES expression plasmid using media containing Geneticin (G418) (700  $\mu$ g/mL). In the screen, the activities of the two different reporter proteins, p53/FL and RL, were measured to determine the effect of the test chemical compounds.

Cells derived from the reporter cell line were maintained in DMEM media  
20 supplemented with antibiotics and 10% FBS. After monomerization of reporter cells with trypsin treatment, an equal number of cells in 30  $\mu$ L volume was dispensed in each well of a 384-well plate ( $5 \times 10^3$  cells/well) using an automatic dispenser (Multidrop 384, Labsystems). After 12-16 hours, test chemical compounds were introduced in the wells using pin arrays at a final concentration of  $\sim 5$   $\mu$ g/mL of the  
25 test compound and pre-incubated with the cells for 2 hours, followed by the addition of adriamycin (1.0  $\mu$ M).

After 24 hours, activities of p53/FL and RL were determined in the same wells using the Dual Luciferase Reporter Assay System (Promega). In the 384-well culture plate, the remaining media was removed from the cells, and the cells were washed  
30 once with 40  $\mu$ L of PBS. The washed cells were then incubated with Passive Lysis Buffer (PLB, 5  $\mu$ L/well) for 20 minutes at room temperature with mild shaking. After the Luciferase Assay Reagent II (LAR II, 25  $\mu$ L/well) was added directly to the cell lysates, FL activity was measured using a luminescence reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences). The Stop & Glo Reagent (25  $\mu$ L/well) was then added to

determine the RL activity. In the screen, test chemical compounds were identified that specifically affect the stabilization of p53-FL without affecting that of RL. The observed effects of these chemical compounds were confirmed by immunoblot analyses of endogenous p53 protein and other endogenous control proteins such as actin.

### **Other Embodiments**

Those of ordinary skill in the art will readily appreciate that the foregoing represents merely certain preferred embodiments of the invention. Various changes and modifications to the procedures and compositions described above can be made without departing from the spirit or scope of the present invention, as set forth in the following claims.

## Claims

What is claimed is:

- 5 1. A method of identifying compounds that affect the transcription of genes regulated by p53, the method comprising the steps of:  
providing one cell line with a construct comprising a p53 binding element operably linked to a first reporter gene;  
providing a second cell line with a construct comprising a p53 binding element  
10 operably linked to a second reporter gene;  
providing a third cell line with a construct comprising a promoter operably linked to a third reporter gene;  
contacting a test compound with cells from each of the three cell lines; and  
determining effect of the test compound on expression of the three reporter  
15 genes.
2. A method of identifying compounds that affect the transcription of genes regulated by p53, the method comprising the steps of:  
providing one cell line with a construct comprising a p53 binding element  
20 operably linked to a first reporter gene;  
providing a second cell line with a construct comprising a p53 binding element operably linked to a second reporter gene;  
contacting a test compound with cells from each of the two cell lines; and  
determining effect of the test compound on expression of the reporter genes.  
25
3. The method of claim 1 or 2 wherein the cell line is derived from a cell line that has a high level of induction of p53 after treatment with a DNA damaging agent.
4. The method of claim 1 or 2 wherein the cell line is derived from a cell line that  
30 expresses wild type p53.
5. The method of claim 1 or 2 wherein the cell line is derived from a cell line that has intact p53-mediated growth arrest pathways in response to DNA damage.

6. The method of claim 1 or 2 wherein the cell line is derived from an animal cell line.
7. The method of claim 1 or 2 wherein the cell line is derived from a mammalian  
5 cell line.
8. The method of claim 1 or 2 wherein the cell line is derived from a human cell line.
- 10 9. The method of claim 1 or 2 wherein the cell line is derived from RKO cell line.
10. The method of claim 1 or 2 wherein the p53 binding element is derived from a p21 gene.  
15
11. The method of claim 1 or 2 wherein the p53 binding element is derived from a bax gene.
12. The method of claim 1 or 2 wherein the p53 binding element is derived from a  
20 14-3-3- gene.
13. The method of claim 1 or 2 wherein the p53 binding element comprises multiple p53 binding sites.
- 25 14. The method of claim 1 wherein the promoter is a constitutive promoter.
15. The method of claim 1 wherein the promoter is a CMV promoter.
16. The method of claim 1 wherein the reporter gene is selected from the groups  
30 consisting of firefly luciferase, secreted alkaline phosphatase, enhanced green fluorescent protein, horseradish peroxidase, and renilla luciferase.

17. The method of claim 1 wherein the reporter gene is selected from the group consisting of firefly luciferase, secreted alkaline phosphatase, renilla luciferase, and  $\beta$ -galactosidase.
- 5 18. The method of claim 1 wherein the reporter gene encodes a protein detectable by an antibody.
19. The method of claim 1 wherein the reporter gene encodes a gene product detectable by a change in absorbance, change in fluorescence, or radio-immuno assay.
- 10 20. A method of identifying compounds that affect p53 stability, the method comprising the steps of:
- providing a cell line transfected with a construct expressing p53-fused to a reporter protein and a control reporter protein;
- 15 contacting a test compound with cells from the cell line;
- contacting cells with a DNA damaging agent; and
- comparing levels of the p53 fusion protein and the control reporter protein.
21. A method of identifying compounds that affect p53 stability, the method
- 20 comprising the steps of:
- providing a cell line transfected with a construct expressing p53-fused to a reporter protein and a control reporter protein, and transfected to express E6;
- contacting a test compound with cells from the cell line;
- contacting cells with a DNA damaging agent; and
- 25 comparing levels of the p53 fusion protein and the control reporter protein.
22. The method of claim 20 or 21 wherein the cell line is derived from a cell line known to contain active p53 turnover pathways.
- 30 23. The method of claim 20 or 21 wherein the cell line is derived from a cell line that has a relatively low steady state level of p53 protein and shows a significant accumulation of p53 protein following treatment with a DNA damaging agent.

24. The method of claim 20 or 21 wherein the DNA damaging agent is a chemotherapeutic agent.
25. The method of claim 20 or 21 wherein the DNA damaging agent is  
5 adriamycin.
26. Inhibitors of p53 identified by the method of claim 1 or claim 20.
27. Activators of p53 identified by the method of claim 1 or claim 20.
- 10 28. A kit useful in identifying compounds that affect the transcription of genes regulated by p53 comprising:  
a first cell line with a construct comprising a p53 binding element operably linked to a first reporter gene;  
15 a second cell line with a construct comprising a p53 binding element operably linked to a second reporter gene; and  
a third cell line with a construct comprising a promoter operably linked to a third reporter gene.
- 20 29. A kit useful in identifying compounds that affect p53 stability comprising:  
a cell line with a construct expressing p52-fused to a reporter protein and a control reporter protein.
30. A method of identifying compounds that affect the transcription of genes  
25 regulated by a protein of interest, the method comprising steps of:  
providing a first cell line with a construct comprising an element known to bind the protein of interest operably linked to a first reporter gene;  
providing a second cell line with a construct comprising an element known to bind the protein of interest operably linked to a second reporter gene;  
30 providing a third cell line with a construct comprising a promoter operably linked to a third reporter gene;  
contacting a test compound with cells from each of the three cell lines; and  
determining the effect of the test compound on expression of the reporter genes.



31. A method of identifying compounds that affect the transcription of genes regulated by a protein of interest, the method comprising steps of:
- providing a first cell line with a construct comprising an element known to
- 5 bind the protein of interest operably linked to a first reporter gene;
- providing a second cell line with a construct comprising an element known to bind the protein of interest operably linked to a second reporter gene;
- contacting a test compound with cells from each of the two cell lines; and
- determining the effect of the test compound on expression of the reporter
- 10 genes.
32. A method of identifying compounds that affect stability of a protein of interest, the method comprising steps of:
- providing a cell line transfected with a construct expressing a first reporter
- 15 protein fused to the protein of interest, and a second control reporter protein;
- contacting a test compound with cells from the cell line;
- contacting the cells with a DNA damaging agent; and
- comparing levels of the first reporter protein and the second reporter protein.
- 20 33. A method of identifying compounds that affect stability of a protein of interest, the method comprising steps of:
- providing a cell line transfected with a construct expressing a first reporter protein fused to the protein of interest, and a second control reporter protein;
- contacting a test compound with cells from the cell line;
- 25 contacting cells with a DNA damaging agent; and
- comparing levels of the first reporter protein and the second reporter protein.

Figure 1




Figure 2





Figure 3






**Figure 4****Figure 5****Figure 6**

Figure 7




Figure 8A

**Multiple (Triple and Double) Readout in One Assay Well**

Facilitates Identification of Chemicals that Specifically Affect p53 Function without Affecting Control Gene Function

Increases Screening Efficiencies by Eliminating Multiple Screenings






Figure 8B



**Figure 9**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number  
**WO 02/044427 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68, G01N 33/50

(21) International Application Number: PCT/US01/51234

(22) International Filing Date: 25 October 2001 (25.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/243,689 27 October 2000 (27.10.2000) US

(71) Applicant (for all designated States except US): **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KIM, Tae Kook** [KR/US]; 11 Beecher Terrace, #2, Newton, MA 02459 (US).

(74) Agent: **BAKER, C., Hunter**; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(88) Date of publication of the international search report:  
14 August 2003

(15) Information about Correction:

[Continued on next page]

(54) Title: CELL BASED TRIPLE READOUT ASSAY SYSTEMS FOR IDENTIFYING COMPOUNDS THAT EFFECT TRANSCRIPTION

DNA Damaging Agent (Adriamycin)



p53-FL	✓
p53-SEAP	✓
CMV-RL	×

Three Reporter Cell lines in One Assay Well

(57) Abstract: The present invention provides assays for identifying compounds that affect the transcriptional activity of a protein of interest or affect the stability of the protein of interest. The triple readout assay system which can be used to identify compounds that affect the transcriptional activity of a protein of interest uses three cell lines to control for non-specific effects such as sequences flanking the inserted gene and cytotoxicity. The double readout assay system assesses protein stability and uses a fusion protein of a reporter and the protein of interest. These assay systems may be particularly useful in identifying compounds that affect transcription factors and tumor suppressors. In a particular embodiment, the tumor suppressor p53 is the target protein being studied.



WO 02/044427 A3



**Previous Correction:**

see PCT Gazette No. 21/2003 of 22 May 2003, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## INTERNATIONAL SEARCH REPORT

Interr Application No

PCT/US 01/51234

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 007 998 A (ROSENBLUM CHARLES I ET AL) 28 December 1999 (1999-12-28)	31
Y	page 1 -page 5	2-13
Y	WO 95 19367 A (JOLLA CANCER RES FOUND) 20 July 1995 (1995-07-20) examples IV,V	2-13
A	WO 97 40379 A (COLD SPRING HARBOR LAB) 30 October 1997 (1997-10-30) page 4, line 18 -page 5, line 18 page 13, line 27 -page 14, line 31	
A	WO 00 47768 A (KNIGHT JULIAN CHARLES ;KWIATKOWSKI DOMINIC PETER (GB); ISIS INNOVA) 17 August 2000 (2000-08-17) page 11, line 25 -page 15, line 4	
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

17 January 2003

Date of mailing of the international search report

24. 04. 03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

## INTERNATIONAL SEARCH REPORT

Inter al Application No

PCI/US 01/51234

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24460 A (TROPIC INC) 10 July 1997 (1997-07-10) ----	
A	KIM T K: "In vitro transcriptional activation of p21 promoter by p53." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 19 MAY 1997, vol. 234, no. 2, 19 May 1997 (1997-05-19), pages 300-302, XP002227598 ISSN: 0006-291X ----	
A	KIM T K ET AL: "Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway." CANCER RESEARCH. UNITED STATES 1 MAR 2000, vol. 60, no. 5, 1 March 2000 (2000-03-01), pages 1153-1156, XP002227599 ISSN: 0008-5472 ----	
A	KIM T ET AL: "Signaling pathways to the assembly of an interferon-beta enhanceosome. Chemical genetic studies with a small molecule." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 2 JUN 2000, vol. 275, no. 22, 2 June 2000 (2000-06-02), pages 16910-16917, XP002227600 ISSN: 0021-9258 -----	

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/51234**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 26, 27  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-19, 28, 30, 31 completely

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 26,27

Present claims 26, 27 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is, however, not to be found in the application. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-19, 28 ,30, 31 completely

A method of identifying compounds that affect the transcription of genes regulated by a protein of interest, especially p53, as detailed in the claims, as well as subject-matter relating thereto.

2. Claims: 20-27, 29, 32, 33 completely

A method of identifying compounds that affect the stability of a protein of interest, especially p53, as detailed in the claims, as well as subject-matter relating thereto.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/51234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6007998 A	28-12-1999	CA 2252443 A EP 0914611 A JP 2000511406 T WO 9740380 A	30-10-1997 12-05-1999 05-09-2000 30-10-1997
WO 9519367 A	20-07-1995	US 5484710 A US 5659024 A US 5908750 A	16-01-1996 19-08-1997 01-06-1999
WO 9740379 A	30-10-1997	US 5861249 A AU 2668397 A US 2001044102 A	19-01-1999 12-11-1997 22-11-2001
WO 0047768 A	17-08-2000	EP 1151137 A	07-11-2001
WO 9724460 A	10-07-1997	AU 732044 B AU 1350297 A CA 2241760 A EP 0874913 A JP 2000513563 T	12-04-2001 28-07-1997 10-07-1997 04-11-1998 17-10-2000

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT


(10) International Publication Number  
**WO 02/044427 A2**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68** (74) Agent: **BAKER, C., Hunter**; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109 (US).
- (21) International Application Number: PCT/US01/51234
- (22) International Filing Date: 25 October 2001 (25.10.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/243,689 27 October 2000 (27.10.2000) US
- (71) Applicant (*for all designated States except US*): **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **KIM, Tae Kook** [KR/US]; 11 Beecher Terrace, #2, Newton, MA 02459 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: DOUBLE AND TRIPLE READOUT ASSAY SYSTEMS

DNA Damaging Agent (Adriamycin)



p53-FL	✓
p53-SEAP	✓
CMV-RL	×

Three Reporter Cell lines in One Assay Well

(57) Abstract: The present invention provides assays for identifying compounds that affect the transcriptional activity of a protein of interest or affect the stability of the protein of interest. The triple readout assay system which can be used to identify compounds that affect the transcriptional activity of a protein of interest uses three cell lines to control for non-specific effects such as sequences flanking the inserted gene and cytotoxicity. The double readout assay system assesses protein stability and uses a fusion protein of a reporter and the protein of interest. These assay systems may be particularly useful in identifying compounds that affect transcription factors and tumor suppressors. In a particular embodiment, the tumor suppressor p53 is the target protein being studied.

WO 02/044427 A2



**Published:**

— *without international search report and to be republished  
upon receipt of that report*

**(15) Information about Correction:**

see PCT Gazette No. 21/2003 of 22 May 2003, Section II

**(48) Date of publication of this corrected version:**

22 May 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## DOUBLE AND TRIPLE READOUT ASSAY SYSTEMS

### Related Applications

5           The present application claims priority to co-pending provisional application, USSN 60/243,689, filed October 27, 2000, which is incorporated herein by reference.

### Background of the Invention

10           Pharmaceutical screens and biological assays have been used for decades in the pharmaceutical and biotech industries to identify lead compounds in the search for new pharmaceutical agents. In the last decade, the chemist's ability to synthesize large numbers of chemical compounds in a short amount of time through techniques such as combinatorial chemistry has greatly increased (for a recent review of the area  
15 of combinatorial chemistry, please see Geysen *et al. Molec. Immunol.* 23:709-715, 1986; Houghton *et al. Nature* 354:84-86, 1991; Frank *Tetrahedron* 48:9217-9232, 1992; Bunin *et al. Proc. Natl. Acad. Sci. USA* 91:4708-4712, 1994; Thompson *et al. Chem. Rev.* 96:555-600, 1996; Keating *et al. Chem. Rev.* 97:449-472, 1997; Gennari *et al. Liebigs Ann./Recueil* 637-647, 1997; Reddington *et al. Science* 280:1735-1737,  
20 1998; each of which is incorporated herein by reference), and it has expanded beyond the capacity of traditional screening methods. Often, thousands to millions of compounds need to be screened to identify those having a desired pharmaceutical property (*e.g.*, anti-neoplastic activity, immunosuppressive activity, *etc.*). Many of the currently available screens are biochemical assay systems in which a compound is  
25 added to a purified or partially purified cell extract to see if it possesses the desired activity. In contrast to the biochemical assay systems, currently available cell-based assay systems identify bioactive molecules that are cell-permeable and work within physiological environments. However, one of the major drawbacks to cell-based assay screens is the high false-positive rate resulting from non-specific effects of the  
30 compound within the cell (for examples, please see Sarver *et al. AIDS Res. Hum. Retroviruses* 8:659-666, 1992; Witvrouw *et al. Antimicrob. Agents Chemother.* 36:2628-2633, 1992; each of which is incorporated herein by reference). Given the fundamental importance of gene regulation in many disease states, one typical cell-based assay measures the activity of a reporter gene under the control of a specific  
35 reporter. However, inhibition of reporter gene expression does not necessarily

indicate a specific interference with promoter activity but could reflect a non-specific inhibition of cellular functions, for example due to cytotoxicity.

One particularly important protein in the study of cancer is the nuclear phosphoprotein, p53. p53 is thought to be mutated in over 50% of human cancers. Mutations in the p53 gene have been found in tumors of colon, lung, breast, ovary, bladder, and several other organs. When mutant forms of the p53 gene are introduced into primary fibroblasts, these cells become immortalized. The wild type p53 gene has been shown to suppress the growth of transformed human cells, but oncogenic forms of p53 lose this suppressor function. Therefore, the p53 gene has been termed a “tumor suppressor” gene. Given the role of p53 in tumorigenesis, it has become an important potential target in the search for new anti-neoplastic agents.

The wild type p53 may be interfered with functionally. For example, a transforming viral infection of the cell can interfere with the p53 protein product. For instance, certain strains of human papillomavirus (HPV) are transforming and are known to interfere with the level of p53 protein in the infected cell because the virus produces a protein, E6, which promotes degradation of the p53 protein.

There is also an interest in p53 because p53 protein is capable of inducing apoptosis in certain cells. In apoptosis, or “programmed cell death”, a series of lethal events for the cell appear to be generated directly as a result of transcription of cellular DNA. For example, lymphocytes exposed to glucocorticoids die by apoptosis. Involution of hormone sensitive tissue such as breast and prostate that occurs when the trophic hormone is removed occurs via apoptosis.

In particular, recent studies have indicated that the introduction of wild type (non-mutated) p53 into transformed cell lines that carry a mutant form of p53 induces the cells to undergo apoptosis with disintegration of nuclear DNA. It is believed that p53 may suppress tumor development by inducing apoptosis, thus modulating cell growth.

Given the importance of p53 in a variety of physiological and disease states, there is a need for cell-based assays with low backgrounds that could be used in screening compounds to identify inhibitors and activators of p53. Moreover, both the rapid increase of new drug targets through genomics research and the availability of vast libraries of chemical compounds create an enormous demand for new technologies which would improve the screening process.

### Summary of the Invention

The present invention provides assay systems for screening chemical compounds to identify activators and inhibitors of proteins of interest (*e.g.*,  
5 transcription factors, enzymes, and tumor suppressors).

In one aspect, the invention provides a cell-based triple readout assay system for identifying compounds that affect transcriptional activity. Three separate cell lines, each containing a different engineered construct, are used. Two have been transfected with a construct comprising a reporter gene and a modulatable  
10 transcriptional regulatory sequence known to bind a selected transcription factor. Each of the two cell lines has a different reporter gene, and the construct is integrated into the genome in a different location to control for the effect of flanking sequences on the transcription of the reporter gene. A third cell line has been transfected with a construct comprising a third reporter gene operably linked to a constitutive promoter.  
15 The third cell line is used to assess general cytotoxicity of the test compound. At least one cell derived from each of the three cell lines is contacted with the test compound, and the levels of the reporter genes are assayed and used to determine the specificity of the test compound on the transcription factor or transcription factor pathway. In a particularly preferred embodiment, the transcription factor of interest is p53.

20 In another aspect, the invention provides a cell-based double readout assay system for identifying compounds that affect protein stability/levels in cells. A fusion protein is created between a protein of interest and a first reporter protein. The fusion protein and a second reporter protein are expressed in a cell line to which the test compound is added. The second reporter protein is used to control for non-specific  
25 effects such as cytotoxicity. The levels of the two proteins (*i.e.*, the fusion protein and the second reporter protein) are measured to assess the specificity of the test compound on the protein of interest. In a particularly preferred embodiment, the two proteins are translated from the same mRNA transcript of an engineered DNA construct.

30 In a particularly preferred embodiment of this aspect of the present invention, the protein of interest is p53. One critical point of regulation of p53 occurs at the protein level. Tumor mutations that affect its conformation typically increase its half-life, in part by inhibiting its degradation by the ubiquitin-proteasome pathway.

Consistent with its critical role in tumor suppression, many oncoproteins including human papillomavirus E6 oncoprotein target the p53 protein and alter its stability.

In yet another aspect, the invention provides chemical inhibitors and activators of p53. Such inhibitors and activators may preferably be identified and/or  
5 characterized using one or both of the inventive triple and double readout assay systems. In certain clinical situations, it is desirable to suppress the cellular effects of p53. For example, p53-dependent apoptosis is thought to contribute to the toxic side effects of anti-cancer treatment with chemotherapy. In certain preferred embodiments of the invention, the p53 inhibitors or activators are provided in the context of a  
10 pharmaceutical composition. In a preferred embodiment, the inhibitors and activators are small molecules.

In another aspect, the invention provides kits for performing the double and triple readout assays. Preferably, an inventive kit contains all the reagents needed to assay a test compound for its effect on transcription and/or protein stability/levels. In  
15 a particularly preferred embodiment, a kit to be used in performing the triple readout assay contains the three cell lines described above. A kit for performing the double readout assay preferably contains a cell line stably transfected with a fusion protein and a second reporter protein. In another preferred embodiment, an inventive kit comprises DNA constructs to be used in transfecting a cell line. Preferred inventive  
20 kits may also contain additional reagents such as media for growing the cells, enzyme substrates (*e.g.*, the substrate of luciferase), DNA damaging compounds (*e.g.*, adriamycin), human papillomavirus E6 oncoprotein, growth factors, *etc.*

### Definitions

25 Unless indicated otherwise, the terms defined below have the following meanings:

“Compound”: The term “compound” or “chemical compound” as used herein can include organometallic compounds, polynucleotides, oligonucleotides, peptides, proteins, organic compounds, metals, transitional metal complexes, and small  
30 molecules. In a particularly preferred embodiment, the term compound refers to small molecules (*e.g.*, preferably, non-peptidic and non-oligomeric) and excludes peptides, polynucleotides, transition metal complexes, metals, and organometallic compounds.

“Constitutive promoter”: The term constitutive promoter refers to a promoter that is always “on”. In other words, genes operably linked to a constitutive promoter are always being transcribed to produce mRNA.

“Construct”: The term construct refers to any polynucleotide that has been  
5 manipulated by the hand of man. Specifically, the construct is isolated from other sequences that are found in the natural state. The construct may be produced by recombinant known in the art such as the polymerase chain reaction. Preferably, the polynucleotide contains various elements that are operably linked, and the construct is introduced into a cell. For example, the construct may contain a promoter operably  
10 linked to a coding sequence, and the construct may be introduced into a cell to cause the cell to produce the encoded protein. In a preferred embodiment, the construct has been created or engineered by the hand of man and does not occur naturally.

“Fusion protein”: The term “fusion protein” refers to a protein comprising two or more polypeptides that, although typically unjoined in their native state, are  
15 joined by their respective amino and carboxyl termini through a peptide linkage to form a single continuous polypeptide. The two or more polypeptide components can be either directly joined or indirectly joined through a peptide linker/spacer. The fusion protein may be translated by a ribosome from mRNA as a single polypeptide, or the polypeptides may be joined using synthetic or enzymatic chemistry.

20 “Modulatable transcriptional regulatory sequence”: The term “modulatable transcriptional regulatory sequence” refers to a DNA sequence capable of regulating the initiation of transcription from the promoter of the reporter gene by the binding of a protein to the sequence. The protein preferably binds a regulatory sequence of the construct in which the promoter, modulatable transcriptional regulatory sequence, and  
25 reporter gene are operably linked, and thereby the protein either up-regulates or down-regulates the transcription from the promoter.

“Operably linked”: The term operably linked refers to two segments of polynucleotide sequence that can affect each other. In a particularly preferred embodiment, one of the two segments is a sequence that binds a protein (*e.g.*,  
30 polymerase, enhancer, and transcription factor), and the binding of the protein to the sequence leads to the transcription of a gene sequence located in the second segment. In another particularly preferred embodiment, the binding of a molecule (*e.g.*, nucleic acid, small molecule, protein, and peptide) to one segment may inhibit or enhance the binding of another molecule (*e.g.*, nucleic acid, small molecule, protein, and peptide)

to the second segment. Preferably, two operably linked segments are covalently linked, but any type of association sufficient to achieve the desired results is considered to be operably linked in the context of the present invention.

“p53”: The term “p53” as used in the present invention refers to both the gene and protein form of p53 or any homolog of p53 or member of the family of p53 genes. The homolog should be at least 50% homologous to the mouse p53 DNA or protein sequence; preferably, at least 60% homologous, and most preferably, greater than 75% homologous. A homolog of p53 may also be identified by its activity such as its ability to suppress the growth of transformed cells. In another preferred embodiment, the homolog of p53 is identified by its location in the genome (*e.g.*, location on the chromosome). In yet another preferred embodiment, the homolog of p53 is able to hybridize to the p53 gene under standard hybridization conditions. p53 may also refer to a fragment of a p53 gene. In certain preferred embodiments, p63, p73, and homologs thereof are considered to be p53 family members. In other preferred embodiments, homologs are at least 50% homologous within the central sequence-specific DNA binding domain, the N-terminal transactivation domains, and/or the C-terminal oligomerization domain, more preferably greater than 60% homologous.

“p53 binding element”: The term “p53 binding element” refers to a sequence of a polynucleotide that binds the p53 protein. In a preferred embodiment, the p53 binding element is the p53 binding element found in the p21, bax, or 14-3-3 gene. The p53 binding element may comprise multiple binding elements (*i.e.*, be multimerized).

“Polynucleotide” or “oligonucleotide”: Polynucleotide or oligonucleotide refers to a polymer of nucleotides. Preferably, the polynucleotide comprises at least three nucleotides, more preferably it comprises at least 10 nucleotides, and most preferably it comprises at least 100 nucleotides. The polymer may include natural nucleosides (*i.e.*, adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (*e.g.*, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (*e.g.*, methylated bases), intercalated bases, modified

sugars (*e.g.*, 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), or modified phosphate groups (*e.g.*, phosphorothioates and 5'-N-phosphoramidite linkages).

“Protein”: According to the present invention, a “protein” comprises a polymer of amino acid residues linked together by peptide bonds. The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. Typically, a protein will be at least three amino acids long. Peptide may refer to an individual peptide or a collection of peptides. Inventive peptides preferably contain only natural amino acids, although non-natural amino acids (*i.e.*, compounds that do not occur in nature but that can be incorporated into a polypeptide chain; see, for example, <http://www.cco.caltech.edu/~dadgrp/Unnatstruct.gif>, which displays structures of non-natural amino acids that have been successfully incorporated into functional ion channels) and/or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in an inventive peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a hydroxyl group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, *etc.* A protein may also be a single molecule or may be a multi-molecular complex. A protein may be a fragment of a naturally occurring protein or peptide. A protein may be naturally occurring, recombinant, or synthetic, or any combination of these.

“Reporter gene”: As used herein, the term “reporter gene” refers to a gene whose transcript or any other gene product (*e.g.*, protein) is detectable. Preferably, the gene product is also quantifiable. More preferably, the gene product is detectable using a standard assay. Most preferably, the gene product is detectable using a standard assay for which the reagents used in the assay are available in a kit. In certain preferred embodiments, the reporter gene encodes a fluorescent protein or an enzyme whose activity is detectable and preferably quantifiable.

“Small Molecule”: As used herein, the term “small molecule” refers to a non-peptidic, non-oligomeric organic compound either synthesized in the laboratory or found in nature. Small molecules, as used herein, can refer to compounds that are “natural product-like”, however, the term “small molecule” is not limited to “natural product-like” compounds. Rather, a small molecule is typically characterized in that it contains several carbon-carbon bonds, and has a molecular weight of less than

1500, although this characterization is not intended to be limiting for the purposes of the present invention. Examples of "small molecules" that occur in nature include, but are not limited to, taxol, dynemicin, and rapamycin. Examples of "small molecules" that are synthesized in the laboratory include, but are not limited to, compounds described in Tan *et al.*, ("Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays" *J. Am. Chem. Soc.* 120:8565, 1998) and pending application number 08/951,930 "Synthesis of Combinatorial Libraries of Compounds Reminiscent of Natural Products", the entire contents of which are incorporated herein by reference.

### Description of the Drawing

Figure 1 shows the transcriptional activation of p53 binding sites. (A) Six copies of p53 binding sites from p21, bax, and 14-3-3 gene, and (B) multiple copies (3, 6, and 12) of the p53 site from 14-3-3 gene were cloned upstream of FL (firefly luciferase) reporter gene. RKO cells were transfected with these plasmids and reporter activities were analyzed after treatment with adriamycin. The results are presented as fold induction, compared to the luciferase activities from cells untreated with adriamycin.

Figure 2 shows a reporter plasmid used for p53 transcriptional activity. Twelve copies of the p53 site from 14-3-3 gene were cloned upstream of FL (firefly luciferase) or SEAP (secreted alkaline phosphatase) reporter gene. This reporter plasmid was used to monitor the transcriptional activity of p53 in cells.

Figure 3 shows transcriptional activation of p53 in a selected stable cell line by DNA damaging agents. (A) FL (firefly luciferase) and (B) SEAP (secreted alkaline phosphatase) reporter activities were determined in the selected clone of stably transfected RKO cells before and after treatment with various DNA damaging agents (adriamycin, UV radiation, mitomycin C, and etoposide). The results are presented as fold induction, compared to the reporter activities from untreated cells.

Figure 4 shows triple readout for p53 transcriptional activity. An equal number of each of the three different RKO reporter cell lines (containing FL and SEAP under the control of p53, an RL under the control of the CMV promoter) was cultured in each well of 384-well plates. Chemicals were transferred into the wells



using pin arrays and preincubated with cells before addition of adriamycin (0.5-1.0  $\mu$ M). After ~24 hours, SEAP activity was determined from culture media using the SEAP Assay System (Promega). FL and RL activities were determined from cell lysates using the Dual Luciferase Assay System (Promega). In the screens, we  
5 identified chemicals that specifically affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

Figure 5 shows stabilization of p53 protein by DNA damaging agents and destabilization of p53 protein by E6 oncoprotein. (A) p53-FL (firefly luciferase) and RL (renilla luciferase) reporter activities were determined in the selected MCF7 clone  
10 before and after treatment with adriamycin. The results are presented as fold induction (p53-FL/RL), compared to the luciferase activities from cells untreated with adriamycin. (B) p53-FL and RL reporter activities were determined in the selected MCF7 clone in the absence or presence of expression of E6 oncoprotein. The results are presented as fold induction (p53-FL/RL), compared to the luciferase activities  
15 from untreated cells.

Figure 6 shows a reporter plasmid used for p53 protein stability and levels. The p53 gene was fused with FL (firefly luciferase) reporter gene. p53-FL fusion protein was expressed together with RL (renilla luciferase) reporter protein through IRES (internal ribosome entry site) under the control of CMV promoter. This reporter  
20 plasmid was used to monitor the stability of p53 protein in cells.

Figure 7 shows the double readout assay for p53 protein stability. A 384-well plate was used to culture MCF7 cells expressing p53-FL and RL proteins, both under control of the CMV promoter. Chemicals were transferred into 384-well plates using pin arrays and preincubated with cells before addition of adriamycin (1  $\mu$ M). After  
25 ~24 hours, p53-FL and RL activities were determined from cell lysates using the Dual Luciferase Assay System (Promega). In the screens, chemical compounds were identified that specifically affect the stability/levels of p53-FL protein, without affecting those of the RL protein.

Figure 8 shows specific chemicals identified from multiple readouts. (A) The  
30 triple and double readout systems were effectively used to screen specific chemicals in a diverse collection of 16,320 synthetic chemicals (Chembridge Corporation), which affect the transcriptional activity and protein stability of p53, respectively. (B) Shown in an example of the selected chemicals which affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

Figure 9 shows double and triple readouts for signaling pathways as a drug-discovery platform. Using multiple readouts, these assays can be used to effectively screen for small molecules specific to p53. Some chemicals may affect transcriptional activity of p53 by up-regulating or down-regulating p53 protein levels.

5 The other chemicals, those whose activity was detected in the triple readout, but not the double readout, presumably modulate p53 transcriptional activity without affecting p53 protein stability. Thus, these readouts enabled us to select and categorize chemicals with potent and specific effects on p53 protein stability and/or transcriptional activity. These assay systems lay out the basis of systematic screening

10 for specific chemical ligands in many other signaling pathways.

### Description of Certain Preferred Embodiments

The present invention provides systems for identifying inhibitors and

15 activators of genes and gene products using cell-based assays with built-in controls to minimize the number of non-specific hits (*i.e.*, background). The inventive assay systems eliminate the need for multiple screenings, which can be costly and time-consuming. The inventive assays determine the effect of a test compound on transcription and levels/stability of the protein of interest.

20

#### *Triple Readout Assay System*

The present invention provides a cell-based triple readout assay system that involves the measurement of the activity or level of a reporter gene product under the control of a specific promoter. Past efforts to assay reporter gene activity were

25 complicated by problems including non-specific inhibition of reporter gene expression, which could be due to non-specific inhibition of cellular functions by cytotoxicity. Before the present invention, in order to distinguish between "true" inhibition and other non-specific effects, a number of time-consuming and costly experiments would need to be performed. Also, another problem associated with

30 many available reporter gene assays is that upon integration of the reporter gene into the genome the transcription of the reporter gene could be influenced by DNA sequences around which the reporter gene was stably inserted.

The inventive triple readout assay overcomes these limitations and therefore reduces or eliminates the need for multiple screenings. The inventive cell-based triple

readout assay involves three separate cell lines. Two of the cell lines express a reporter gene under the control of the same modulatable transcriptional regulatory sequence. The third cell line expresses a reporter gene under the control of a constitutive promoter. The influence of the DNA sequences adjacent to where the reporter gene was stably inserted is controlled for by the first two cell lines. General effects of cytotoxicity or inhibition of gene expression are eliminated using the third cell line that uses a constitutive promoter.

In a particularly preferred embodiment, the transcription factor being studied is p53. In unstressed cells, p53 is present at low levels and exists in a latent, inactive form. Levels and/or activity of p53 increase in response to a variety of stimuli including genotoxic stress. Active p53 protein accumulates in the nucleus, binding to its responsive DNA elements and inducing the transcription of its target genes. Under inappropriate growth conditions, p53 can integrate a variety of signals to the specific gene regulation for protection of cells against neoplastic transformation. Consistent with its critical role in tumor suppression, the majority of the p53 mutations associated with human tumors, in addition to many oncoproteins, decrease p53's sequence-specific DNA binding and transcriptional activity. Thus, small molecules that modulate transcriptional activity of p53 are important for therapeutic purposes.

Any cell line may be used in developing the cell lines used in the inventive triple readout assay. The cells may be animal, plant, bacterial, or fungal cells. In a preferred embodiment, the cell line is a mammalian cell line. In a particularly preferred embodiment, the cell line is a human cell line. The chosen cell line may satisfy other requirements particular to the protein of interest and known to one of skill in this art; for example, if one were interested in regulating p53-dependent transcription, the cell line should preferably (1) express wild-type p53; (2) show a high level of induction of p53 after treatment with DNA damaging agents; and/or (3) have functionally intact p53-mediated growth arrest pathways. A particularly preferred cell line used in studying p53 is the RKO cell line, a colon cancer cell line. Those of ordinary skill in this art will readily appreciate the multitude of cell lines that could be utilized in the assay systems and would be able to choose a cell line based on multiple factors affecting the gene or protein being studied in the inventive assay.

The modulatable transcriptional regulatory sequence is modulated by the protein of interest or by a protein which is secondarily or indirectly modulated by the protein of interest. In some embodiments, the protein of interest directly modulates

transcription by binding to the regulatory sequence directly or indirectly. In other embodiments, the protein of interest acts indirectly to modulate transcription. The protein of interest may act indirectly through a single- or multi-step biological pathway. The responsiveness of the regulatory sequence may depend on the presence  
5 or absence, or activity level, of the protein of interest.

To give but one example, in which p53 is the protein of interest, the modulatable transcriptional regulatory sequence comprises at least one p53 binding element. Any p53 binding element may be operably linked to the reporter gene. In a preferred embodiment, the p53 binding element shows a high level of induction of the  
10 operably linked reporter gene in response to DNA damage. Examples of p53 binding elements can be found in the following three target genes: p21, bax, and 14-3-3. In a particularly preferred embodiment, the p53 binding element is multimerized. For example, six to twelve copies of the element may result in nearly saturated levels of p53 induction. In other embodiments, the p53 may act as a repressor, and down-  
15 regulation of the reporter gene is assayed.

The reporter gene may encode any gene product (*i.e.*, transcript and protein) that is detectable by any known method (*e.g.*, Northern analysis, Western analysis, radio-immuno assay, enzymatic assay, change in fluorescence, change in absorbance, *etc.*), and preferably the level of the gene product is quantifiable by any known  
20 method (please see, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); the treatise, *Methods in Enzymology* (Academic Press, Inc., N.Y.); *Immunochemical Methods in Cell and Molecular Biology* (Mayer and Walker, eds., Academic Press, London,  
25 1987); Ausubel *et al.* *Current Protocols in Molecular Biology* (John Wiley & Sons, Inc., New York, 1999); *Transcription and Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Handbook of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); each of which is incorporated herein by reference). In a preferred embodiment, the reporter gene is an enzyme (*e.g.*, kinases, phosphatases,  
30 luciferases,  $\beta$ -galactosidase, reductases, synthases, horseradish peroxidase, synthetases, *etc.*). The enzyme itself may be detectable or the activity of the enzyme may be used to indirectly measure the level of the enzyme.

In a particularly preferred embodiment of the present invention, at least one of the reporter genes of the assay system encodes a luciferase protein. Luciferases may

come from any organism including the North American firefly, *Photinus pyralis*, the sea pansy, *Renilla reniformis*, and the bacterium, *Vibrio fischeri*. A more complete description of luciferases and their use as transcriptional reporters can be found in De Wet *et al.* ("Cloning of firefly luciferase cDNA and the expression of active luciferase  
5 in *Escherichia coli*" *Proc. Natl. Acad. Sci. USA* 82:7870, 1985; incorporated herein by reference) and Engebrecht *et al.* ("Measuring gene expression with light" *Science* 227:1345, 1985; incorporated herein by reference).

In another particularly preferred embodiment of the present invention, at least one of the reporter genes of the assay system encodes an alkaline phosphatase. The  
10 phosphatase gene may be from any species. A particularly preferred alkaline phosphatase is secreted alkaline phosphatase (SEAP).

In another particularly preferred embodiment, the reporter gene encodes an enhanced green fluorescent protein (EGFP). For more details in the use of enhanced green fluorescent protein as a reporter, please see Cinelli *et al.* (*Photochem.*  
15 *Photobiol.* 71(6):771-776, 2000; incorporated herein by reference); Kiss-Toth *et al.* (*J. Immunol. Methods* 239(1-2):125-135, 2000; incorporated herein by reference); and Millet *et al.* (*Toxicol. Sci.* 55(1):69-77, 2000; incorporated herein by reference).

#### *Double Readout Assay System*

20 The level of certain proteins in the cell regulates many cellular processes. Therefore, the degradation, stability, and accumulation of proteins are highly controlled in the cell. For example, one pathway which regulates the degradation of proteins is the ubiquitin-proteasome pathway. The ability to regulate specific protein degradation pathways or to affect the stability of specific proteins would allow for a  
25 new approach in treating diseases such as cancer, autoimmune diseases, and neurological diseases.

Traditional assays for identifying compounds that effect protein stability have been hampered by the large number of non-specific effects. For example, an increase in protein stability may reflect a non-specific inhibition of cellular functions by the  
30 cytotoxic effect of the compound rather than a specific effect on the protein's stability.

To give but one example of a protein whose level is critical in a cellular process, p53 is a tumor suppressor protein whose level has been found to be important in tumorigenesis. Mutations in p53 that affect its conformation typically increase its

half-life, in part by inhibiting its degradation by the ubiquitin-proteasome pathway. In unstressed cells, p53 is present at low levels and exists in a latent, inactive form. If the cell is then stressed (e.g., genotoxic stress), the levels and/or activity of p53 increase. Active p53 protein then accumulates in the nucleus of the cell, binds to its responsive DNA elements, and induces the expression of its target genes. Under inappropriate growth conditions, p53 can integrate a variety of signals for protection of the cells against neoplastic transformation. Consistent with p53's critical role in tumor suppression, many oncoproteins target p53 and its protein stability, including the human papillomavirus E6 oncoprotein. Therefore, compounds that could modulate p53 protein stability are important for therapeutic purposes.

In the inventive double readout assay system, the protein of interest (e.g., p53) is fused to a first reporter protein, for example using standard recombinant DNA techniques (Ausubel *et al.*, *Current Protocols in Molecular Biology* (John Wiley & Sons, Inc., New York, 1999); Sambrook, Fritsch, and Maniatis, eds., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., (Cold Spring Harbor Laboratory Press, 1989); each of which is incorporated herein by reference). Both the fusion protein and a control reporter protein are expressed in the cell. The cell(s) are contacted with various test compounds, and the levels of the fusion protein and the control reporter protein are measured. The level of the fusion protein when compared to the level of the control reporter protein would allow for the identification of compounds specifically affecting the stability of the protein of interest due to their effects on the ratio of fusion protein to control. In a preferred embodiment, at least a 50% change in the level of the fusion protein when compared to that of the control reporter protein is considered to be a hit, more preferably there is at least a 150% change, and most preferably there is at a 500% change.

The reporter proteins may be any protein or peptide as described above in the triple readout assay system. Preferably, the presence of the protein or peptide can be detected using standard techniques (e.g., radioimmunoassay, radio-labeling, immunoassay, assay for enzymatic activity, absorbance, fluorescence, luminescence, and Western blot). More preferably, the level of each of the reporter proteins is easily quantifiable using standard techniques even at low levels. In a preferred embodiment, the reporter proteins are related so that their levels are easily comparable.

In a particularly preferred embodiment, the reporter proteins are luciferases as described above in the triple readout assay system. Preferably, the luciferases are

distinguishable from one another if two luciferases are used as the reporter proteins. In a particularly preferred embodiment, one reporter protein is firefly luciferase (FL) from *Photinus pyralis*, and the other is *Renilla* luciferase (RL) from *Renilla reniformis*. The protein levels may be determined using the Dual-Luciferase<sup>®</sup> Assay System (Promega) (*Dual-Luciferase<sup>®</sup> Reporter 1000 Assay System*, Technical Manual No. 046, Promega Corp., Madison, WI, 1999; incorporated herein by reference).

Preferably, the genes encoding the fusion protein and the control reporter protein are transcribed at substantially the same level. In a particularly preferred embodiment, the two genes of the proteins are transcribed together to create one transcript. An internal ribosome entry site (IRES) may be inserted between the two genes to ensure translation of both encoded proteins. In another particularly preferred embodiment, the two genes are under the control of the same promoter sequences and regulatory elements.

As with the inventive triple readout assay system, any cell line in which the proteins are expressed may be employed in the inventive double readout system. Preferably, in the example of p53, the cell line contains active p53 turnover pathways, the steady-state level of p53 protein is relatively low, and the level of p53 protein significantly increases following stress stimuli (*e.g.*, treatment with chemotherapeutic DNA damaging agents). In a particularly preferred embodiment, the cell line is MCF7.

In another particularly preferred embodiment, the cell line is transfected with the fusion protein gene and the control reporter gene, and the resulting cells are tested for stabilization of p53 protein after treatment with adriamycin. Preferably, the clones show a 5-fold increase in the level of the fusion protein. More preferably, the clones show a 10-fold increase; and most preferably, the clones show a 20-fold increase.

The cell line may be transfected with other genes that affect p53 degradation. In a particularly preferred embodiment, the cell line is transfected with the human papillomavirus oncoprotein E6. Many other oncoproteins may be used in this embodiment of the invention. As will be appreciated by one of skill in this art, any gene that may affect the stability/level of the protein being investigated may be transfected into the cell line.

### *Test Compounds*

The compounds to be screened in the inventive double and triple readout assays may be provided by any means known in the art. The test compounds may be polynucleotides, peptides, proteins, small molecules, organic molecules, inorganic molecules, peptidomimetics, antibodies, or other chemical compounds. The compounds may be prepared by purification or isolation from a source (*e.g.*, plant, fungus, animal, bacteria, soil sample, *etc.*), or by synthesis. The synthesized compounds may be created by more conventional one-by-one synthetic methods or by combinatorial chemistry methods through rapid parallel and/or automated synthesis. The compounds may be provided in crude or pure forms. The compounds may be natural products or derivatives of natural products. In another preferred embodiment, the compounds are provided from the historical compound files of large pharmaceutical and chemical companies. Preferably, the compounds are provided as libraries of chemical compounds.

The compounds are screened by the methods described above to identify activators and inhibitors of the protein/gene of interest. To give but one example, the methods may be used to identify activators and inhibitors of p53. Chemical inhibitors of p53 are useful in preventing or minimizing the toxic side effects derived from p53-dependent apoptosis (*e.g.*, those side effects seen in individuals undergoing chemotherapy and radiation therapy). Chemical activators of p53 would be useful in developing new anti-neoplastic agents. In a particularly preferred embodiment, the compounds may activate or inhibit the protein/gene of interest by two-fold, more preferably five-fold, and most preferably ten-fold.

### *Kits*

The present invention also provides kits for performing the double and triple readout assays. Preferably, these kits include all the reagents necessary to assay a test compound or library of test compounds. The kits may include cell lines, stably transfected cell lines as described above, media, growth factors, DNA damaging agents (*e.g.*, bleomycin, adriamycin), human papillomavirus E6 oncoprotein, DNA constructs, enzyme substrate (*e.g.*, substrate of the luciferase enzyme being assayed for), *etc.*



These and other aspects of the present invention will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain particular embodiments of the invention but are not intended to limit its scope, as defined by the claims.

5

### Examples

#### Example 1- Triple Readout for p53 Transcriptional Activity

Three different reporter cell lines (one containing FL under the control of p53, a second containing SEAP under the control of p53, and a third containing RL under the control of the CMV promoter) were established by selection with hygromycin (400 µg/mL) after transfection of RKO cells with the reporter plasmid (see Figure 2). In the screen, cells derived from the three cell lines were mixed, and the activities of the three different reporter proteins were assayed in a single well after incubation with chemicals as described below.

The cells lines were maintained in McCoy media supplemented with antibiotics and 10% heat-inactivated fetal bovine serum (FBS) to exclude SEAP activity in the serum. After monomerization of reporter cells with trypsin, an equal number of cells from each of the three cells lines was mixed in a flask, and 30 µL of the resulting cell mixture was dispensed in each well of a 384-well plate ( $5 \times 10^3$  cells/well) using an automatic dispenser (Multidrop 384, Labsystems). After 12-16 hours, test chemical compounds were introduced into the wells using pin arrays resulting in a final concentration of ~5 µg/mL of the test compound and pre-incubated with the cells for 2 hours followed by the addition of adriamycin (0.5-1.0 µM). After 24 hours, activities of reporter proteins were determined using corresponding assay systems according to the manufacturer's instructions.

For the SEAP assay, 5 µL of each of the culture media was transferred to another 384-well plate and incubated with 55 µL of the SEAP assay mixture (EscAPe SEAP Chemiluminescent Assay System, Clontech Laboratories) at room temperature for 20 minutes. SEAP activity was measured using a luminescent reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences).

The Dual Luciferase Reporter Assay System (Promega) was used for FL and RL assays. In the original 384-well culture plate, the remaining media was removed, and the cells were washed once with 40 µL of phosphate buffer-saline (PBS). The washed cells were incubated with Passive Lysis Buffer (PLB, 5 µL/well) for 20

minutes at room temperature with mild-shaking. Then, the Luciferase Assay Reagent II (LAR II, 25  $\mu$ L/well) was added directly to the cell lysates, and FL activity was determined using a luminescent reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences). After measuring the FL activity, Stop & Glo Reagent (25  $\mu$ L/well) was added, and the RL activity was determined. In the screens, chemical compounds were identified that specifically affected p53-dependent FL and SEAP expression, without affecting CMV promoter-driven RL expression.

#### Example 2 – Double Readout Assay for p53 Protein Stability

A plasmid expressing both the p53/FL fusion gene and RL gene under the control of a single CMV promoter with an internal ribosome entry site (IRES) was created (see Figure 6). Co-expression of p53/FL and RL proteins by taking advantage of the internal ribosome entry site makes it possible to normalize the levels of p53/FL with those of RL in various assay conditions. The reporter cell line was established by selecting MCF7 cells transfected with the IRES expression plasmid using media containing Geneticin (G418) (700  $\mu$ g/mL). In the screen, the activities of the two different reporter proteins, p53/FL and RL, were measured to determine the effect of the test chemical compounds.

Cells derived from the reporter cell line were maintained in DMEM media supplemented with antibiotics and 10% FBS. After monomerization of reporter cells with trypsin treatment, an equal number of cells in 30  $\mu$ L volume was dispensed in each well of a 384-well plate ( $5 \times 10^3$  cells/well) using an automatic dispenser (Multidrop 384, Labsystems). After 12-16 hours, test chemical compounds were introduced in the wells using pin arrays at a final concentration of  $\sim 5$   $\mu$ g/mL of the test compound and pre-incubated with the cells for 2 hours, followed by the addition of adriamycin (1.0  $\mu$ M).

After 24 hours, activities of p53/FL and RL were determined in the same wells using the Dual Luciferase Reporter Assay System (Promega). In the 384-well culture plate, the remaining media was removed from the cells, and the cells were washed once with 40  $\mu$ L of PBS. The washed cells were then incubated with Passive Lysis Buffer (PLB, 5  $\mu$ L/well) for 20 minutes at room temperature with mild shaking. After the Luciferase Assay Reagent II (LAR II, 25  $\mu$ L/well) was added directly to the cell lysates, FL activity was measured using a luminescence reader (Wallac VICTOR<sup>2</sup>, PerkinElmer Life Sciences). The Stop & Glo Reagent (25  $\mu$ L/well) was then added to

determine the RL activity. In the screen, test chemical compounds were identified that specifically affect the stabilization of p53-FL without affecting that of RL. The observed effects of these chemical compounds were confirmed by immunoblot analyses of endogenous p53 protein and other endogenous control proteins such as

5 actin.

### **Other Embodiments**

Those of ordinary skill in the art will readily appreciate that the foregoing

10 represents merely certain preferred embodiments of the invention. Various changes and modifications to the procedures and compositions described above can be made without departing from the spirit or scope of the present invention, as set forth in the following claims.

## Claims

What is claimed is:

- 5 1. A method of identifying compounds that affect the transcription of genes regulated by p53, the method comprising the steps of:
  - providing one cell line with a construct comprising a p53 binding element operably linked to a first reporter gene;
  - providing a second cell line with a construct comprising a p53 binding element
  - 10 operably linked to a second reporter gene;
  - providing a third cell line with a construct comprising a promoter operably linked to a third reporter gene;
  - contacting a test compound with cells from each of the three cell lines; and
  - determining effect of the test compound on expression of the three reporter
  - 15 genes.
2. A method of identifying compounds that affect the transcription of genes regulated by p53, the method comprising the steps of:
  - providing one cell line with a construct comprising a p53 binding element
  - 20 operably linked to a first reporter gene;
  - providing a second cell line with a construct comprising a p53 binding element operably linked to a second reporter gene;
  - contacting a test compound with cells from each of the two cell lines; and
  - determining effect of the test compound on expression of the reporter genes.
  - 25
3. The method of claim 1 or 2 wherein the cell line is derived from a cell line that has a high level of induction of p53 after treatment with a DNA damaging agent.
4. The method of claim 1 or 2 wherein the cell line is derived from a cell line that
- 30 expresses wild type p53.
5. The method of claim 1 or 2 wherein the cell line is derived from a cell line that has intact p53-mediated growth arrest pathways in response to DNA damage.

6. The method of claim 1 or 2 wherein the cell line is derived from an animal cell line.
7. The method of claim 1 or 2 wherein the cell line is derived from a mammalian  
5 cell line.
8. The method of claim 1 or 2 wherein the cell line is derived from a human cell line.
- 10 9. The method of claim 1 or 2 wherein the cell line is derived from RKO cell line.
10. The method of claim 1 or 2 wherein the p53 binding element is derived from a p21 gene.  
15
11. The method of claim 1 or 2 wherein the p53 binding element is derived from a bax gene.
12. The method of claim 1 or 2 wherein the p53 binding element is derived from a  
20 14-3-3- gene.
13. The method of claim 1 or 2 wherein the p53 binding element comprises multiple p53 binding sites.
- 25 14. The method of claim 1 wherein the promoter is a constitutive promoter.
15. The method of claim 1 wherein the promoter is a CMV promoter.
16. The method of claim 1 wherein the reporter gene is selected from the groups  
30 consisting of firefly luciferase, secreted alkaline phosphatase, enhanced green fluorescent protein, horseradish peroxidase, and renilla luciferase.

17. The method of claim 1 wherein the reporter gene is selected from the group consisting of firefly luciferase, secreted alkaline phosphatase, renilla luciferase, and  $\beta$ -galactosidase.
- 5 18. The method of claim 1 wherein the reporter gene encodes a protein detectable by an antibody.
19. The method of claim 1 wherein the reporter gene encodes a gene product detectable by a change in absorbance, change in fluorescence, or radio-immuno assay.
- 10 20. A method of identifying compounds that affect p53 stability, the method comprising the steps of:
- providing a cell line transfected with a construct expressing p53-fused to a reporter protein and a control reporter protein;
  - 15 contacting a test compound with cells from the cell line;
  - contacting cells with a DNA damaging agent; and
  - comparing levels of the p53 fusion protein and the control reporter protein.
21. A method of identifying compounds that affect p53 stability, the method
- 20 comprising the steps of:
- providing a cell line transfected with a construct expressing p53-fused to a reporter protein and a control reporter protein, and transfected to express E6;
  - contacting a test compound with cells from the cell line;
  - contacting cells with a DNA damaging agent; and
  - 25 comparing levels of the p53 fusion protein and the control reporter protein.
22. The method of claim 20 or 21 wherein the cell line is derived from a cell line known to contain active p53 turnover pathways.
- 30 23. The method of claim 20 or 21 wherein the cell line is derived from a cell line that has a relatively low steady state level of p53 protein and shows a significant accumulation of p53 protein following treatment with a DNA damaging agent.

24. The method of claim 20 or 21 wherein the DNA damaging agent is a chemotherapeutic agent.
25. The method of claim 20 or 21 wherein the DNA damaging agent is  
5 adriamycin.
26. Inhibitors of p53 identified by the method of claim 1 or claim 20.
27. Activators of p53 identified by the method of claim 1 or claim 20.
- 10 28. A kit useful in identifying compounds that affect the transcription of genes regulated by p53 comprising:  
a first cell line with a construct comprising a p53 binding element operably linked to a first reporter gene;  
15 a second cell line with a construct comprising a p53 binding element operably linked to a second reporter gene; and  
a third cell line with a construct comprising a promoter operably linked to a third reporter gene.
- 20 29. A kit useful in identifying compounds that affect p53 stability comprising:  
a cell line with a construct expressing p52-fused to a reporter protein and a control reporter protein.
30. A method of identifying compounds that affect the transcription of genes  
25 regulated by a protein of interest, the method comprising steps of:  
providing a first cell line with a construct comprising an element known to bind the protein of interest operably linked to a first reporter gene;  
providing a second cell line with a construct comprising an element known to bind the protein of interest operably linked to a second reporter gene;  
30 providing a third cell line with a construct comprising a promoter operably linked to a third reporter gene;  
contacting a test compound with cells from each of the three cell lines; and  
determining the effect of the test compound on expression of the reporter genes.

31. A method of identifying compounds that affect the transcription of genes regulated by a protein of interest, the method comprising steps of:
- providing a first cell line with a construct comprising an element known to bind the protein of interest operably linked to a first reporter gene;
  - providing a second cell line with a construct comprising an element known to bind the protein of interest operably linked to a second reporter gene;
  - contacting a test compound with cells from each of the two cell lines; and
  - determining the effect of the test compound on expression of the reporter genes.
32. A method of identifying compounds that affect stability of a protein of interest, the method comprising steps of:
- providing a cell line transfected with a construct expressing a first reporter protein fused to the protein of interest, and a second control reporter protein;
  - contacting a test compound with cells from the cell line;
  - contacting the cells with a DNA damaging agent; and
  - comparing levels of the first reporter protein and the second reporter protein.
33. A method of identifying compounds that affect stability of a protein of interest, the method comprising steps of:
- providing a cell line transfected with a construct expressing a first reporter protein fused to the protein of interest, and a second control reporter protein;
  - contacting a test compound with cells from the cell line;
  - contacting cells with a DNA damaging agent; and
  - comparing levels of the first reporter protein and the second reporter protein.



1/5




FIG. 1A




FIG. 1B




FIG. 2





FIG. 3

2/5

DNA Damaging Agent (Adriamycin)



Three Reporter Cell lines in One Assay Well

FIG. 4




FIG. 5A




FIG. 5B




FIG. 6

3/5




FIG. 7

### **Multiple (Triple and Double) Readout in One Assay Well**

Facilitates Identification of Chemicals that Specifically Affect p53 Function without Affecting Control Gene Function

Increases Screening Efficiencies by Eliminating Multiple Screenings




FIG. 8A

4/5




FIG. 8B

5/5




FIG. 9

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**